With IBD, Inflammatory Markers Could Indicate CRC Risk
the MPR take:
Patients with inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis are at a greater risk of developing colorectal cancer (CRC), which is believed to be linked to persistent inflammation. This is the first study to evaluate an association between C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) elevation and risk of CRC in patients with IBD. This study of 3,145 patients with at least 1 CRP value and 4,008 with at least 1 ESR value were evaluated for subsequent CRC diagnosis; thirty-three individuals in the CRP group and 102 in the ESR group received a CRC diagnosis during a median follow-up of five years (median age of individuals: 55 years). The researchers discovered a significant increase in CRC risk with both CRP (P trend=.017; odds ratio for quartile 4 vs. quartile 1, 2.72; 95% confidence interval, 0.95–7.76) and ESR elevation (odds ratio, 2.06; 95% confidence interval, 1.14–3.74) (P trend=.007). Physicians should discuss the risk of CRC with their IBD patients and develop a treatment plan to minimize persistent inflammation.
Patients with inflammatory bowel diseases (IBDs) are at increased risk of colorectal cancer (CRC). Persistent inflammation is hypothesized to increase risk of CRC in patients with IBD; however, the few studies in this area have been restricted to cross-sectional assessments of histologic severity. Publishing in Clinical Gastroenterology and Hepatology, Ashwin N.
READ FULL ARTICLE From Gastro